Reporting and evaluaton of HIV-related clinical endpoints in two multicenter international clinical trials

HIV Clinical Trials

Volumn 7, Issue 3, 2006, Pages 125-141

  Lifson, Alan R ^a   Rhame, Frank S ^b   Belloso, Waldo H ^c   Dragsted, Ulrik B ^d   El Sadr, Wafaa M ^e   Gatell, Jose M ^f   Hoy, Jennifer F ^g   Krum, Eric A ^a   Nelson, Ray ^a   Pedersen, Court ^h   Pett, Sarah L ⁱ   Davey Jr , Richard T ^j   Neaton, James ^k   Abrams, Donald ^k   Cahn, Pedro ^k   Clotet, Bonaventura ^k   Cooper, David ^k   Darbyshire, Janet ^k   Sandra, Lehrman ^k   Emery, Sean ^k   Hengge, Ulrich ^k   Lane, H Clifford ^k   Lange, Joep ^k   Levy, Guido ^k   Levy, Yves ^k   Lundgren, Jens ^k   Mitsuyasu, Ron ^k   Routy, Jean Pierre ^k   Tambussi, Giuseppe ^k   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b ABBOTT NORTHWESTERN HOSPITAL   (United States)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^d HVIDOVRE HOSPITAL   (Denmark)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f UNIVERSITY OF BARCELONA   (Spain)

^g MONASH UNIVERSITY   (Australia)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

^k NONE

more..

Author keywords

Clinical endpoints; Clinical trials; Human immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT; RECOMBINANT INTERLEUKIN 2; INTERLEUKIN 2;

ARTICLE; BACTERIAL PNEUMONIA; BRAIN INFECTION; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOSPORIDIOSIS; DISEASE COURSE; ESOPHAGUS CANDIDIASIS; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; INTERNATIONAL COOPERATION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUBERCULOSIS; UTERINE CERVIX CANCER; WASTING SYNDROME; BIOASSAY; EVALUATION; METHODOLOGY; STANDARD;

ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; MULTICENTER STUDIES; TREATMENT OUTCOME;

EID: 33748155708     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/7MER-XFA7-1762-E2WR     Document Type: Article

References (29)

1. Lagakos SW. Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties. Clin Infect Dis. 1993;16(suppl 1):S22-25.
2. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers - Are we being naive? J Infect Dis. 1997;175:237-246.
3. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate endpoints: a meta-analysis. AIDS Res Hum Retroviruses. 2000;16:1123-1133.
4. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet. 1994;343:871-881.
5. El-Sadr W, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, CO. Abstract 106LB.
6. Davey RT, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA. 2000;284:183-189.
7. Forum for Collaborative HIV Research. Immune-based therapies: a review of clinical endpoints used in trials of selected immunologic agents. HIV Clin Trials. 2002;3:58-88.
8. Amato DA, Lagakos SW. Considerations in the selection of end points for AIDS clinical trials. J Acquir Immune Defic Syndr. 1990;3(suppl 2):S64-68.
9. Green LA, Rhame FS, Price RW, et al. Experience with a cross-study endpoint review committee for AIDS clinical trials. AIDS. 1998;12:1983-1990.
10. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992:41(RR-17):1-19.
11. Neaton JD, Wentworth DN, Rhame F, et al. Considerations in choice of a clinical endpoint for AIDS clinical trials. Stat Med. 1994;13:2107-2125.
12. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med. 1996;124:633-642.
13. Mocroft A, Youle M, Phillips AN, et al. The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Arch Intern Med. 1998;158:491-497.
14. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet. 1994: 344:110-113.
15. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med. 1993; 329:297-303.
16. 3. Ann Intern Med. 1995; 123:561-571.
17. Eisenbud R, Assmann SF, Kalish LA, et al. Differences in difficulty adjudicating clinical events in patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2001;28:43-46.
18. Levy Y, Mitsuyasu R, Tambusi G, et al. CD4 count increases in patients with CD4 counts of 50-300 treated with intermittent IL-2: immunologic results from the Study of IL-2 in Combination with Active Antiretroviral Therapy (SILCAAT) Trial. Paper presented at: Ninth European AIDS Conference; October 2003; Warsaw, Poland. Abstract F 14/3.
19. Emery S, Abrams DI, Cooper DA, et al. The Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial: rationale, design, and methods of ESPRIT. Control Clin Trials. 2002;23:198-220.
20. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
21. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis. 1988;158:1079-1083.
22. Rothman KJ. Modern Epidemiology. Boston: Little, Brown and Company;1986:84-89.
23. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: Greater precision but with greater uncertainty? JAMA. 2003;289:2554-2559.
24. Chi GYH. Some issues with composite endpoints in clinical trials. Fundam Clin Pharmacol. 2005;19:609-619.
25. Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437-443.
26. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr. 2003;34:379-386.
27. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004;22:19-22.
28. Ioannidis JPA, Evans SJW, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781-788.
29. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021-2029.